Cellulitis Antibiotic Selection

Treat diffuse, nonpurulent cellulitis without systemic signs with an agent active against streptococci. IDSA notes that MRSA is an unusual cause of typical cellulitis; do not add MRSA coverage routinely in an otherwise typical nonpurulent presentation. IDSAIDSASkin and Soft Tissue Infections - IDSA

Reclassify the episode as purulent when there is purulent drainage, pustules, or an abscess. Staphylococcus aureus, including MRSA, is then a common pathogen, and incision and drainage is primary management when an abscess is present. Obtain a culture from purulent material when feasible if infection is severe, recurrent, or not responding to empiric therapy. BMJ+2BMJAdvances in the diagnosis and management of skin and soft tissue ...PubMedWSES/GAIS/WSIS/SIS-E/AAST global clinical pathways for patients ...PubMedManagement of complicated skin and soft tissue infections with a special focus on the role of newer antibiotics

Escalate beyond routine outpatient selection for systemic signs, SIRS, septic shock, active chemotherapy or other major immunocompromise, or concern for a deeper severe soft-tissue infection. In severely compromised patients, IDSA recommends broad coverage with vancomycin plus piperacillin-tazobactam or cefepime; use local antibiograms to refine empiric therapy. IDSA+2IDSASkin and Soft Tissue Infections - IDSABMJAdvances in the diagnosis and management of skin and soft tissue ...PubMedTreatment of severe skin and soft tissue infections: a review - PMC

Cephalexin 500 mg orally every 6 hours is a cited regimen for nonpurulent cellulitis. For patients with a severe beta-lactam allergy, clindamycin 300 to 450 mg orally every 6 hours is an alternative, but clindamycin selection should account for local resistance among streptococci and S. aureus and its increased risk of Clostridioides difficile infection. PubMed+1PubMedCellulitis - StatPearls - NCBI Bookshelf - NIHBMJAdvances in the diagnosis and management of skin and soft tissue ...

If the presentation is nonpurulent but MRSA risk is present—penetrating trauma, MRSA infection elsewhere, MRSA nasal colonization, injection drug use, or SIRS—use therapy active against both MRSA and streptococci rather than cephalexin alone. IDSAIDSASkin and Soft Tissue Infections - IDSA A cited oral approach for cellulitis with MRSA risk factors is TMP-SMX 800/160 mg twice daily plus cephalexin 500 mg every 6 hours for 5 days; clindamycin 300 to 450 mg every 6 hours is an alternative when TMP-SMX cannot be used. PubMedPubMedCellulitis - StatPearls - NCBI Bookshelf - NIH

For purulent infection or high local MRSA prevalence, oral TMP-SMX, doxycycline, or clindamycin are guideline-supported MRSA-active options. The global pathway lists TMP-SMX 160/800 to 320/1600 mg every 12 hours, doxycycline 100 mg every 12 hours, or minocycline 100 mg every 12 hours for outpatient or step-down therapy in MRSA-risk settings. BMJ+1BMJAdvances in the diagnosis and management of skin and soft tissue ...PubMedWSES/GAIS/WSIS/SIS-E/AAST global clinical pathways for patients ...

For patients with nonpurulent cellulitis who have systemic signs such as fever or rigors and require IV therapy, cited options include cefazolin or ceftriaxone; vancomycin or linezolid are options when MRSA-active therapy is required. BMJBMJAdvances in the diagnosis and management of skin and soft tissue ... IDSA recommends vancomycin or another agent effective against both MRSA and streptococci for severe nonpurulent cellulitis associated with specified MRSA risks or SIRS. IDSAIDSASkin and Soft Tissue Infections - IDSA

Do not assume IV therapy improves outcomes solely because cellulitis appears extensive. In a multicenter clinical-trial analysis, patients selected for IV treatment more often had CRP greater than 100 mg/L, skin involvement greater than 5% of body surface area, or at least one SIRS criterion; available trials did not demonstrate superiority of IV over oral therapy or benefit from courses longer than 5 days. These markers may identify patients clinicians commonly treat more aggressively but do not independently establish a requirement for IV treatment. ScienceDirectScienceDirectAntibiotic route and duration of therapy for cellulitis: data extracted from a multi-center clinical trial

Obtain blood cultures before antibiotics when sepsis is suspected, because pre-antibiotic cultures can permit later de-escalation. Avoid indiscriminate cultures in uncomplicated cellulitis; culture-directed therapy is particularly useful in severe, recurrent, or treatment-nonresponsive infection. CDC+1CDC[PDF] Blood Culture Contamination: An Overview for Infection Control and ...PubMedManagement of complicated skin and soft tissue infections with a special focus on the role of newer antibiotics

When fluctuance, focal purulent drainage, or an abscess accompanies cellulitis, perform incision and drainage as primary management. Antibiotics should be considered in addition to drainage based on disease severity and patient factors; absent drainage is associated with treatment failure in outpatient skin and soft-tissue infection cohorts. PubMed+2PubMedWSES/GAIS/WSIS/SIS-E/AAST global clinical pathways for patients ...BMJAdvances in the diagnosis and management of skin and soft tissue ...ScienceDirectEmpiric Outpatient Therapy with Trimethoprim-Sulfamethoxazole, Cephalexin, or Clindamycin for Cellulitis - ScienceDirect

Use a 5-day treatment course when improvement is evident by day 5; a 5- to 6-day streptococcal-active course is recommended for nonpurulent cellulitis. Extend therapy to 7 to 10 days when symptoms have not resolved at day 5 or when complications develop. acpjournals+2acpjournalsAppropriate Use of Short-Course Antibiotics in Common InfectionsPubMedClinical Guidelines for the Antibiotic Treatment for Community-Acquired Skin and Soft Tissue InfectionPubMedWSES/GAIS/WSIS/SIS-E/AAST global clinical pathways for patients ...

Reassess patients with minimal improvement by 48 hours. Confirm that the episode was nonpurulent versus abscess-associated, identify whether drainage is needed, review adherence and antibiotic selection, and obtain culture material from purulence when infection is severe, recurrent, or nonresponsive. PubMed+1PubMedCellulitis - StatPearls - NCBI Bookshelf - NIHPubMedManagement of complicated skin and soft tissue infections with a special focus on the role of newer antibiotics

Do not use a presumed high community MRSA rate alone to override the typical nonpurulent cellulitis pathway when there is no purulence or IDSA-defined MRSA risk factor. MRSA is described as an unusual cause of typical cellulitis, whereas abscess-associated infection is usually caused by S. aureus. IDSA+1IDSASkin and Soft Tissue Infections - IDSAPubMedWSES/GAIS/WSIS/SIS-E/AAST global clinical pathways for patients ...

Avoid routinely extending therapy beyond 5 days in a patient who is improving. International recommendations vary from 5 to 10 to 14 days, but systematic-review evidence found no demonstrated benefit for treatment longer than 5 days in uncomplicated cellulitis. ScienceDirect+1ScienceDirectRoute and duration of antibiotic therapy in acute cellulitis: A systematic review and meta-analysis of the effectiveness and harms of antibiotic treatmentPubMedClinical Guidelines for the Antibiotic Treatment for Community-Acquired Skin and Soft Tissue Infection

Do not base antibiotic narrowing on a superficial wound culture from intact nonpurulent cellulitis. When microbiology is needed, collect pus from an abscess or wound, tissue, aspirate, or other adequate clinical specimen; severe, recurrent, and nonresponsive disease are the highest-yield situations for culture-directed change. cdn clinicaltrials+1cdn clinicaltrials7-161PubMedManagement of complicated skin and soft tissue infections with a special focus on the role of newer antibiotics